(1) New York, New York, USA 3.1 Introduction Despite numerous attempts to develop new classes of compounds for either the progression or symptomatic treatment of Alzheimer’s disease, there have…
(1) Toyonaka, Japan 1.1 From the First Report of Alzheimer’s Disease to Its Establishment as a Concept An illness, later to be named Alzheimer’s disease (AD), was first reported…
(1) Toyonaka, Japan 6.1 Introduction Symptomatic drugs for Alzheimer’s disease (AD) target neurotransmitters. The cholinergic nervous system is closely involved in memory and learning. The AD brain shows a…
(1) Toyonaka, Japan 2.1 Introduction From 1976 to 1977, three British groups established the acetylcholine (ACh) hypothesis, which claims that the activity of choline acetyltransferase (ChAT), an ACh synthase,…
, Ignacio Flores2 and Roser Ribosa-Nogué3 (1) Barcelona, Spain (2) Servicio de Neurología, Hospital San Martín, La Plata, Buenos Aires, Argentina (3) Unitat de Memòria, Servei de Neurologia, Hospital de la Santa…
(1) Southhampton, United Kingdom 5.1 Introduction Memantine is a noncompetitive, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. It is licensed for the treatment of moderate to severe AD in the USA…
